GS-5816: a DAA with pan-genotypic HCV activity

The availability of a safe, highly effective, pangenotypic regimen for the treatment of HCV infection would have a major impact on global disease prevalence, as it would be suitable for treatment of all infected persons regardless of genotype. Results of a new phase 1 study demonstrate the safety and potent pan-genotypic HCV activity of GS-5816, a novel inhibitor of the HCV nonstructural NS5A protein. GS-5816 administered at doses ranging from 5 ...

Read More


Real-world impact of sofosbuvir HCV regimens

New study addresses the real-world effectiveness of sofosbuvir (SOF)-based anti-HCV regimens in a diverse patient population consisting of difficult to treat patients. More than a quarter of the assessed US Veterans Affairs (VA) population with chronic HCV infection were African American, almost 90% were over the age of 55, over a third were overweight, and substantial proportions were treatment experienced and had advanced liver disease. ...

Read More


Addressing the Restricted Use of DAA therapies

Results of a new US cost effectiveness study indicate that effective direct acting antiviral (DAA) therapies should be not be restricted to only those HCV-infected patients with advanced fibrosis. Authors note that as a society, we have an opportunity to eliminate hepatitis C by taking appropriate and timely steps, and we should be willing to pay for the current HCV therapies by providing additional resources and giving hepatitis C the attent...

Read More


HCV DAAs and Severe Renal Impairment

New report provides vital information needed by clinicians to treat HCV in patients with severe renal impairment with the approved DAAs simeprevir and sofosbuvir. Available clinical information on the use of sofosbuvir in patients with severe renal impairment is minimal, and there are currently no approved direct acting antiviral (DAA) treatments in this population. A report recently published online in Journal of Hepatology details the ...

Read More


Interventions in the HCV care continuum

New systematic review in the journal International Journal of Drug Policy discusses published evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Authors note that primary care settings represent key opportunities for HCV care linkage interventions, often within clinics that have prolonged engagement with homeless, substance using populations, or people who inject drugs. The ...

Read More


Liver transplant failure risk: Females with HCV

Prospective Liver Match study unequivocally shows that female gender is a risk factor for graft loss after liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Women lose their graft more frequently than men, secondary to more aggressive recurrent HCV infection. This study also confirms that the use of elderly donors is a strong predictor of poor graft outcome in HCV-infected lung transplant recipients. The prospective Liver ...

Read More


Coffee Decreases HCV Advanced Fibrosis Risk

New study indicates that an average daily intake of an estimated 100 mg of caffeine from coffee, tea, or soda is associated with an approximately one-third reduction in odds of advanced fibrosis, although higher intake does not seem to confer any additional benefit. Interestingly, tea intake in those who do not consume coffee may also be associated with a decreased risk of advanced fibrosis. Study authors noted an average of 100 mg or more of ...

Read More


Hepatitis C RAVs are Not a Barrier to Retreatment

Study published in the journal Hepatology suggests that sofosbuvir plus peginterferon and ribavirin for 12 weeks is effective and safe in patients who have not achieved SVR with prior regimens of one or more direct-acting antiviral (DAA) agents plus peginterferon and ribavirin. High rates of SVR12 are achieved regardless of the presence of resistance associated variants (RAVs) to the previous agents (Pol S, et al. Hepatology. 2015 Apr 6. doi: ...

Read More


Dr. E Lebovics: Post-EASL 2015 HCV Interview

During our last interview, you mentioned that extending the use of all oral, interferon-free, hepatitis C regimens to special populations including those with decompensated cirrhosis, post-transplant, and renal failure is an area of great interest. We would like to hear your thoughts on relevant clinical data presented at The International Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver, in ...

Read More


Beneficial Effect of Statins on HCV Infection

In a large, national cohort study assessing the impact of statin use upon progression of fibrosis in an unselected group of patients with various stages and genotypes of HCV, controlling for known confounders, statin use was significantly associated with decreased progression of fibrosis independent of having attained an SVR. This is the first study to demonstrate that statin use is significantly associated with increased SVR rates and decreased ...

Read More